Cancer associated fibroblasts and tumor growth: Focus on multiple myeloma

Cancers

Volumn 6, Issue 3, 2014, Pages 1363-1381

  De Veirman, Kim ^a   Rao, Luigia ^a,b   De Bruyne, Elke ^a   Menu, Eline ^a   Van Valckenborgh, Els ^a   Van Riet, Ivan ^a,c   Frassanito, Maria Antonia ^b   Di Marzo, Lucia ^b   Vacca, Angelo ^b   Vanderkerken, Karin ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Cancer associated fibroblasts; Hypoxia; Multiple myeloma

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALVASCULIN; CD38 ANTIGEN; COLLAGEN; CYTOKINE; GROWTH FACTOR; MATRIX METALLOPROTEINASE; PODOPLANIN; SYNDECAN 1; TENASCIN; THROMBOSPONDIN; TRANSCRIPTION FACTOR RUNX2; TUMOR MARKER;

CANCER ASSOCIATED FIBROBLAST; CELL ACTIVATION; CELL COMPONENT; CELL POPULATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; ENZYME ACTIVATION; HUMAN; HYPOXIA; METASTASIS; MOLECULAR MECHANICS; MULTIPLE MYELOMA; NONHUMAN; REVIEW; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84903521284     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6031363     Document Type: Review

References (93)

1. Castells, M.; Thibault, B.; Delord, J. P.; Couderc, B. Implication of tumor microenvironment in chemoresistance: Tumor-associated stromal cells protect tumor cells from cell death. Int. J. Mol. Sci. 2012, 13, 9545-9571.
2. Madar, S.; Goldstein, I.; Rotter, V. Cancer associated fibroblasts-More than meets the eye. Trends Mol. Med. 2013, 19, 447-453.
3. Xing, F.; Saidou, J.; Watabe, K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front. Biosci. 2010, 15, 166-179.
4. Orimo, A.; Weinberg, R. A. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol. Ther. 2007, 6, 618-619.
5. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6, 392-401.
6. Hu, M.; Polyak, K. Microenvironmental regulation of cancer development. Curr. Opin. Genet. Dev. 2008, 18, 27-34.
7. Franco, O. E.; Shaw, A. K.; Strand, D. W.; Hayward, S. W. Cancer associated fibroblasts in cancer pathogenesis. Semin. Cell Dev. Biol. 2010, 21, 33-39.
8. Brentnall, T. A.; Lai, L. A.; Coleman, J.; Bronner, M. P.; Pan, S.; Chen, R. Arousal of cancer-associated stroma: Overexpression of palladin activates fibroblasts to promote tumor invasion. PLoS One 2012, 7, e30219.
9. Liao, D.; Luo, Y.; Markowitz, D.; Xiang, R.; Reisfeld, R. A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009, 4, e7965.
10. Spaeth, E. L.; Dembinski, J. L.; Sasser, A. K.; Watson, K.; Klopp, A.; Hall, B.; Andreeff, M.; Marini, F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4, e4992.
11. McAnulty, R. J. Fibroblasts and myofibroblasts: Their source, function and role in disease. Int. J. Biochem. Cell Biol. 2007, 39, 666-671.
12. Sugimoto, H.; Mundel, T. M.; Kieran, M. W.; Kalluri, R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 2006, 5, 1640-1646.
13. True, L. D.; Zhang, H.; Ye, M.; Huang, C. Y.; Nelson, P. S.; von Haller, P. D.; Tjoelker, L. W.; Kim, J. S.; Qian, W. J.; Smith, R. D.; et al. CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod. Pathol. 2010, 23, 1346-1356.
14. Pula, B.; Jethon, A.; Piotrowska, A.; Gomulkiewicz, A.; Owczarek, T.; Calik, J.; Wojnar, A.; Witkiewicz, W.; Rys, J.; Ugorski, M.; et al. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology 2011, 59, 1249-1260.
15. Strutz, F.; Okada, H.; Lo, C. W.; Danoff, T.; Carone, R. L.; Tomaszewski, J. E.; Neilson, E. G. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 1995, 130, 393-405.
16. Schurch, W.; Seemayer, T. A.; Lagace, R.; Gabbiani, G. The intermediate filament cytoskeleton of myofibroblasts: An immunofluorescence and ultrastructural study. Virchows. Arch. A Pathol. Anat. Histopathol. 1984, 403, 323-336.
17. Wolf, B. B.; Quan, C.; Tran, T.; Wiesmann, C.; Sutherlin, D. On the edge of validation-Cancer protease fibroblast activation protein. Mini Rev. Med. Chem. 2008, 8, 719-727.
18. Nakagawa, H.; Liyanarachchi, S.; Davuluri, R. V.; Auer, H.; Martin, E. W., Jr.; de la Chapelle, A.; Frankel, W. L. Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene 2004, 23, 7366-7377.
19. Saad, S.; Gottlieb, D. J.; Bradstock, K. F.; Overall, C. M.; Bendall, L. J. Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res. 2002, 62, 283-289.
20. Kikuchi, Y.; Kashima, T. G.; Nishiyama, T.; Shimazu, K.; Morishita, Y.; Shimazaki, M.; Kii, I.; Horie, H.; Nagai, H.; Kudo, A.; et al. Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. J. Histochem. Cytochem 2008, 56, 753-764.
21. Erez, N.; Truitt, M.; Olson, P.; Arron, S. T.; Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κb-dependent manner. Cancer Cell 2010, 17, 135-147.
22. Lotti, F.; Jarrar, A. M.; Pai, R. K.; Hitomi, M.; Lathia, J.; Gantt, G. A. J.; Sukhdeo, K.; DeVecchio, J.; Vasanji, A.; Leahy, P.; et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J. Exp. Med. 2013, 210, 2851-2872.
23. Direkze, N. C.; Hodivala-Dilke, K.; Jeffery, R.; Hunt, T.; Poulsom, R.; Oukrif, D.; Alison, M. R.; Wright, N. A. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 2004, 64, 8492-8495.
24. Xu, J.; Lu, Y.; Qiu, S.; Chen, Z. N.; Fan, Z. A novel role of EMMPRIN/CD147 in transformation of quiescent fibroblasts to cancer-associated fibroblasts by breast cancer cells. Cancer Lett. 2013, 335, 380-386.
25. Mitra, A. K.; Zillhardt, M.; Hua, Y.; Tiwari, P.; Murmann, A. E.; Peter, M. E.; Lengyel, E. Micrornas reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012, 2, 1100-1108.
26. Paunescu, V.; Bojin, F. M.; Tatu, C. A.; Gavriliuc, O. I.; Rosca, A.; Gruia, A. T.; Tanasie, G.; Bunu, C.; Crisnic, D.; Gherghiceanu, M.; et al. Tumour-associated fibroblasts and mesenchymal stem cells: More similarities than differences. J. Cell Mol. Med. 2011, 15, 635-646.
27. Mi, Z.; Bhattacharya, S. D.; Kim, V. M.; Guo, H.; Talbot, L. J.; Kuo, P. C. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 2011, 32, 477-487.
28. Ostman, A.; Augsten, M. Cancer-associated fibroblasts and tumor growth-Bystanders turning into key players. Curr. Opin. Genet. Dev. 2009, 19, 67-73.
29. Zeisberg, E. M.; Potenta, S.; Xie, L.; Zeisberg, M.; Kalluri, R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007, 67, 10123-10128.
30. Franco, O. E.; Jiang, M.; Strand, D. W.; Peacock, J.; Fernandez, S.; Jackson, R. S.; Revelo, M. P.; Bhowmick, N. A.; Hayward, S. W. Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res. 2011, 71, 1272-1281.
31. Gabbiani, G. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 2003, 200, 500-503.
32. Peng, Q.; Zhao, L.; Hou, Y.; Sun, Y.; Wang, L.; Luo, H.; Peng, H.; Liu, M. Biological characteristics and genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in human breast cancer. PLoS One 2013, 8, e60321.
33. Shimoda, M.; Mellody, K. T.; Orimo, A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin. Cell Dev. Biol. 2010, 21, 19-25.
34. De Wever, O.; Nguyen, Q. D.; van Hoorde, L.; Bracke, M.; Bruyneel, E.; Gespach, C.; Mareel, M. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 2004, 18, 1016-1018.
35. Murata, T.; Mizushima, H.; Chinen, I.; Moribe, H.; Yagi, S.; Hoffman, R. M.; Kimura, T.; Yoshino, K.; Ueda, Y.; Enomoto, T.; et al. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. Cancer Res. 2011, 71, 6633-6642.
36. Orimo, A.; Gupta, P. B.; Sgroi, D. C.; Arenzana-Seisdedos, F.; Delaunay, T.; Naeem, R.; Carey, V. J.; Richardson, A. L.; Weinberg, R. A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121, 335-348.
37. Ronnov-Jessen, L.; Petersen, O. W. Induction of α-smooth muscle actin by transforming growth factor-β 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab. Invest. 1993, 68, 696-707.
38. Kojima, Y.; Acar, A.; Eaton, E. N.; Mellody, K. T.; Scheel, C.; Ben-Porath, I.; Onder, T. T.; Wang, Z. C.; Richardson, A. L.; Weinberg, R. A.; et al. Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. USA 2010, 107, 20009-20014.
39. Massague, J. TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13, 616-630.
40. Webber, J.; Steadman, R.; Mason, M. D.; Tabi, Z.; Clayton, A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010, 70, 9621-9630.
41. Li, Q.; Zhang, D.; Wang, Y.; Sun, P.; Hou, X.; Larner, J.; Xiong, W.; Mi, J. MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation. Sci. Rep. 2013, 3, doi: 10.1038/srep02038.
42. Neufert, C.; Becker, C.; Tureci, O.; Waldner, M. J.; Backert, I.; Floh, K.; Atreya, I.; Leppkes, M.; Jefremow, A.; Vieth, M.; et al. Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J. Clin. Invest. 2013, 123, 1428-1443.
43. Pietras, K.; Pahler, J.; Bergers, G.; Hanahan, D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008, 5, e19.
44. Akashi, T.; Minami, J.; Ishige, Y.; Eishi, Y.; Takizawa, T.; Koike, M.; Yanagishita, M. Basement membrane matrix modifies cytokine interactions between lung cancer cells and fibroblasts. Pathobiology 2005, 72, 250-259.
45. Micke, P.; Ostman, O. Tumour-Stroma interaction: Cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004, 45, S163-S175.
46. Chiquet, M.; Gelman, L.; Lutz, R.; Maier, S. From mechanotransduction to extracellular matrix gene expression in fibroblasts. Biochim. Biophys. Acta 2009, 1793, 911-920.
47. Gillette, M.; Bray, K.; Blumenthaler, A.; Vargo-Gogola, T. P190B RhoGAP overexpression in the developing mammary epithelium induces TGFβ-dependent fibroblast activation. PLoS One 2013, 8, e65105.
48. Barcellos-Hoff, M. H.; Ravani, S. A. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 2000, 60, 1254-1260.
49. Trimis, G.; Chatzistamou, I.; Politi, K.; Kiaris, H.; Papavassiliou, A. G. Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. Hum. Mol. Genet. 2008, 17, 3596-3600.
50. Hu, M.; Peluffo, G.; Chen, H.; Gelman, R.; Schnitt, S.; Polyak, K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc. Natl. Acad. Sci. USA 2009, 106, 3372-3377.
51. Olumi, A. F.; Grossfeld, G. D.; Hayward, S. W.; Carroll, P. R.; Tlsty, T. D.; Cunha, G. R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59, 5002-5011.
52. Li, Q.; Wang, W.; Yamada, T.; Matsumoto, K.; Sakai, K.; Bando, Y.; Uehara, H.; Nishioka, Y.; Sone, S.; Iwakiri, S.; et al. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am. J. Pathol. 2011, 179, 1483-1493.
53. Kinoshita, H.; Hirata, Y.; Nakagawa, H.; Sakamoto, K.; Hayakawa, Y.; Takahashi, R.; Nakata, W.; Sakitani, K.; Serizawa, T.; Hikiba, Y.; et al. Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis. PLoS One 2013, 8, e60914.
54. Pietras, K.; Ostman, A. Hallmarks of cancer: Interactions with the tumor stroma. Exp. Cell Res. 2010, 316, 1324-1331.
55. Matsuo, Y.; Ochi, N.; Sawai, H.; Yasuda, A.; Takahashi, H.; Funahashi, H.; Takeyama, H.; Tong, Z.; Guha, S. CXCL8/IL-8 and CXCL12/SDF-1α co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int. J. Cancer 2009, 124, 853-861.
56. Vermeulen, L.; de Sousa E Melo, F.; van der Heijden, M.; Cameron, K.; de Jong, J. H.; Borovski, T.; Tuynman, J. B.; Todaro, M.; Merz, C.; Rodermond, H.; et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12, 468-477.
57. Tsuyada, A.; Chow, A.; Wu, J.; Somlo, G.; Chu, P.; Loera, S.; Luu, T.; Li, A. X.; Wu, X.; Ye, W.; et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012, 72, 2768-2779.
58. Maman, S.; Edry-Botzer, L.; Sagi-Assif, O.; Meshel, T.; Yuan, W.; Lu, W.; Witz, I. P. The metastatic microenvironment: Lung-derived factors control the viability of neuroblastoma lung metastasis. Int. J. Cancer 2013, 133, 2296-2306.
59. Gupta, G. P.; Massague, J. Cancer metastasis: Building a framework. Cell 2006, 127, 679-695.
60. Gaggioli, C.; Hooper, S.; Hidalgo-Carcedo, C.; Grosse, R.; Marshall, J. F.; Harrington, K.; Sahai, E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007, 9, 1392-1400.
61. Goicoechea, S. M.; Garcia-Mata, R.; Staub, J.; Valdivia, A.; Sharek, L.; McCulloch, C. G.; Hwang, R. F.; Urrutia, R.; Yeh, J. J.; Kim, H. J.; et al. Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts. Oncogene 2014, 33, 1265-1273.
62. Duda, D. G.; Duyverman, A. M.; Kohno, M.; Snuderl, M.; Steller, E. J.; Fukumura, D.; Jain, R. K. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. USA 2010, 107, 21677-21682.
63. Karnoub, A. E.; Dash, A. B.; Vo, A. P.; Sullivan, A.; Brooks, M. W.; Bell, G. W.; Richardson, A. L.; Polyak, K.; Tubo, R.; Weinberg, R. A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449, 557-563.
64. Grum-Schwensen, B.; Klingelhofer, J.; Berg, C. H.; El-Naaman, C.; Grigorian, M.; Lukanidin, E.; Ambartsumian, N. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res. 2005, 65, 3772-3780.
65. Pena, C.; Cespedes, M. V.; Lindh, M. B.; Kiflemariam, S.; Mezheyeuski, A.; Edqvist, P. H.; Hagglof, C.; Birgisson, H.; Bojmar, L.; Jirstrom, K.; et al. STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res. 2012, 73, 1287-1297.
66. Raz, Y.; Erez, N. An inflammatory vicious cycle: Fibroblasts and immune cell recruitment in cancer. Exp. Cell Res. 2013, 319, 1596-1603.
67. Servais, C.; Erez, N. From sentinel cells to inflammatory culprits: Cancer-associated fibroblasts in tumour-related inflammation. J. Pathol. 2013, 229, 198-207.
68. Fu, Z.; Zuo, Y.; Li, D.; Xu, W.; Chen, H.; Zheng, S. The crosstalk: Tumor-infiltrating lymphocytes rich in regulatory T cells suppressed cancer-associated fibroblasts. Acta Oncol. 2013, 52, 1760-1770.
69. Kobayashi, N.; Miyoshi, S.; Mikami, T.; Koyama, H.; Kitazawa, M.; Takeoka, M.; Sano, K.; Amano, J.; Isogai, Z.; Niida, S.; et al. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res. 2010, 70, 7073-7083.
70. Müerköster, S.; Wegehenkel, K.; Arlt, A. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1β. Cancer Res. 2004, 64, 1331-1337.
71. Provenzano, P. P.; Cuevas, C.; Chang, A. E.; Goel, V. K.; von Hoff, D. D.; Hingorani, S. R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012, 21, 418-429.
72. Crawford, Y.; Kasman, I.; Yu, L.; Zhong, C.; Wu, X.; Modrusan, Z.; Kaminker, J.; Ferrara, N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15, 21-34.
73. Lemaire, M.; Deleu, S.; De Bruyne, E.; van Valckenborgh, E.; Menu, E.; Vanderkerken, K. The microenvironment and molecular biology of the multiple myeloma tumor. Adv. Cancer Res. 2011, 110, 19-42.
74. Manier, S.; Sacco, A.; Leleu, X.; Ghobrial, I. M.; Roccaro, A. M. Bone marrow microenvironment in multiple myeloma progression. J. Biomed. Biotechnol. 2012, 2012, 1-5.
75. Jobin, M. E.; Fahey, J. L.; Price, A. Z. Long-term establishment of a human plasmacyte cell line derived from a patient with IgD multiple myeloma. J. Exp. Med. 1974, 140, 494-507.
76. Frassanito, M. A.; Rao, L.; Moschetta, M.; Ria, R.; di Marzo, L.; de Luisi, A.; Racanelli, V.; Catacchio, I.; Berardi, S.; Basile, A.; et al. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: In vitro and in vivo studies. Leukemia 2013, doi: 10.1038/leu.2013.254.
77. Slany, A.; Haudek-Prinz, V.; Meshcheryakova, A.; Bileck, A.; Lamm, W. Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma. J. Proteome Res. 2014, 13, 844-854.
78. Fuhler, G. M.; Baanstra, M.; Chesik, D.; Somasundaram, R.; Seckinger, A.; Hose, D.; Peppelenbosch, M. P.; Bos, N. A. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp. Cell Res. 2010, 316, 1816-1828.
79. Van Valckenborgh, E.; Matsui, W.; Agarwal, P.; Lub, S.; Dehui, X.; De Bruyne, E.; Menu, E.; Empsen, C.; van Grunsven, L.; Agarwal, J.; et al. Tumor-initiating capacity of CD138-and CD138+ tumor cells in the 5T33 multiple myeloma model. Leukemia 2012, 26, 1436-1439.
80. Celegato, M.; Borghese, C.; Casagrande, N.; Carbone, A.; Colombatti, A.; Aldinucci, D. Bortezomib down-modulates the survival factor interferon regulatory factor 4 in hodgkin lymphoma cell lines and decreases the protective activity of hodgkin lymphoma-associated fibroblasts. Leukemia Lymphoma 2014, 55, 149-159.
81. Hu, J.; van Valckenborgh, E.; Menu, E.; De Bruyne, E.; Vanderkerken, K. Understanding the hypoxic niche of multiple myeloma: Therapeutic implications and contributions of mouse models. Dis. Model. Mech. 2012, 5, 763-771.
82. Cosse, J. P.; Michiels, C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med. Chem. 2008, 8, 790-797.
83. Giaccia, A. J.; Schipani, E. Role of carcinoma-associated fibroblasts and hypoxia in tumor progression. Curr. Top. Microbiol. Immunol. 2010, 345, 31-45.
84. Colla, S.; Storti, P.; Donofrio, G.; Todoerti, K.; Bolzoni, M.; Lazzaretti, M.; Abeltino, M.; Ippolito, L.; Neri, A.; Ribatti, D.; et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: Role on the transcriptional and proangiogenic profiles of CD138+ cells. Leukemia 2010, 24, 1967-1970.
85. Hu, J.; Handisides, D. R.; van Valckenborgh, E.; De Raeve, H.; Menu, E.; Vande Broek, I.; Liu, Q.; Sun, J. D.; van Camp, B.; Hart, C. P.; et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 2010, 116, 1524-1527.
86. Storti, P.; Bolzoni, M.; Donofrio, G.; Airoldi, I.; Guasco, D.; Toscani, D.; Martella, E.; Lazzaretti, M.; Mancini, C.; Agnelli, L.; et al. Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia 2013, 27, 1697-1706.
87. Azab, A. K.; Hu, J.; Quang, P.; Azab, F.; Pitsillides, C.; Awwad, R.; Thompson, B.; Maiso, P.; Sun, J. D.; Hart, C. P.; et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012, 119, 5782-5794.
88. Martinez-Outschoorn, U. E.; Trimmer, C.; Lin, Z.; Whitaker-Menezes, D.; Chiavarina, B.; Zhou, J.; Wang, C.; Pavlides, S.; Martinez-Cantarin, M. P.; Capozza, F.; et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NF-κb activation in the tumor stromal microenvironment. Cell Cycle 2010, 9, 3515-3533.
89. Toullec, A.; Gerald, D.; Despouy, G.; Bourachot, B.; Cardon, M.; Lefort, S.; Richardson, M.; Rigaill, G.; Parrini, M. C.; Lucchesi, C.; et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol. Med. 2010, 2, 211-230.
90. Chiavarina, B.; Whitaker-Menezes, D.; Migneco, G.; Martinez-Outschoorn, U. E.; Pavlides, S.; Howell, A.; Tanowitz, H. B.; Casimiro, M. C.; Wang, C.; Pestell, R. G.; et al. HIF1-α functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle 2010, 9, 3534-3551.
91. Higgins, D. F.; Kimura, K.; Iwano, M.; Haase, V. H. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle 2008, 7, 1128-1132.
92. Ino, Y.; Yamazaki-Itoh, R.; Oguro, S.; Shimada, K.; Kosuge, T.; Zavada, J.; Kanai, Y.; Hiraoka, N. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One 2013, 8, e55146.
93. Kim, J. W.; Evans, C.; Weidemann, A.; Takeda, N.; Lee, Y. S.; Stockmann, C.; Branco-Price, C.; Brandberg, F.; Leone, G.; Ostrowski, M. C.; et al. Loss of fibroblast hif-1alpha accelerates tumorigenesis. Cancer Res. 2012, 72, 3187-3195.